IQVIA™ (NYSE: IQV) today announced the launch of Orchestrated Patient Engagement (OPE), a new cloud-based software as a service (SaaS) solution that helps close the gap between life sciences companies and patients. The OPE SaaS solution is powered by Belong.Life technology to allow life sciences customers to facilitate interactions and gain insights from patients who opt-in, assisting in the commercialization process.
“Engagement with patients is a huge area of opportunity for life sciences companies,” said Mike Townsend, research director for IDC Health Insights, a leading analyst firm that helps organizations make fact-based technology decisions to achieve their key business objectives. “Patients want to know about their conditions and treatment plans and to engage with communities that understand what they are going through. Educated patients and caregivers with access to such communities are more engaged in the treatment journey and more likely to adhere to treatment plans, which leads to improved patient health outcomes.”
IQVIA’s OPE creates unique advantages and drives value throughout the commercialization process. For instance, OPE provides access to information for patients during the pre-launch phase, empowering life sciences customers to develop a deep understanding of patient needs. At launch, OPE delivers hyper-targeted awareness campaigns to patients who joined the program. For existing marketed therapies, OPE facilitates direct engagement to understand compliance patterns and drive adherence.
“We believe that engaging patients effectively demands domain expertise and experience backed by disruptive technology,” said Eliran Malki, co-founder and chief executive officer of Belong.Life. “Our market-proven platform puts the focus on patients with hyper-personalized education and an AI-enhanced user experience empowering and connecting them with their entire ecosystem.”
IQVIA OPE is designed to protect patients’ data and provide transparency for its users, by involving patients in decisions about how their information might be used throughout the patient journey. Patients can choose to join and opt-out at any time. IQVIA OPE will be available in the United States in the fourth quarter of 2019.
“IQVIA Technologies is excited to launch its latest innovative solution, OPE, which helps bridge the gap between life sciences companies and patients,” said Tal Rosenberg, senior vice president, Global Technology Solutions at IQVIA. “OPE puts patients in the center, providing them with tools to manage their treatments more effectively, and empowering them with knowledge when they need it.”
Today’s announcement was made at the eyeforpharma Patient Summit USA in Philadelphia. To learn more about the IQVIA and Belong partnership, as well as OPE, please visit the IQVIA exhibit (booth #3).
Founded in 2015 by noted entrepreneurs Eliran Malki, Irad Deutsch and Ohad Rubin after each lost relatives to cancer, Belong – Beating Cancer Together is a free patient navigation app that allows cancer patients and their support network to explore and better manage their treatment journey while improving their quality of life. The Belong global community gains access to a proprietary big data platform and machine learning technology that enables people to connect, receive and share clinical information anonymously and to privately discuss urgent issues related to their condition. The Belong Patient Engagement Platform provides healthcare organizations with an end-to-end solution that includes personalized and configurable patient engagement tools, navigation and management services. Today, Belong is the world’s largest digital cancer patient platform and has partnerships with the American Cancer Society, Colorectal Cancer Canada, Janssen Pharmaceuticals and others. The company also conducts research, collaborates with leading universities and has published research with The American Society of Clinical Oncology (ASCO) and other organizations. To learn more, visit https://belong.life/.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 61,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.